Global Pulmonary Arterial Hypertension (PAH) Medicine Market Growth 2022-2028

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Annual Sales 2017-2028

2.1.2 World Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Medicine by Geographic Region, 2017, 2022 & 2028

2.1.3 World Current & Future Analysis for Pulmonary Arterial Hypertension (PAH) Medicine by Country/Region, 2017, 2022 & 2028

2.2 Pulmonary Arterial Hypertension (PAH) Medicine Segment by Type

2.2.1 Calcium Channel Blockers

2.2.2 Novel Targeted Drugs

2.2.3 Other

2.3 Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type

2.3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2017-2022)

2.3.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue and Market Share by Type (2017-2022)

2.3.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Sale Price by Type (2017-2022)

2.4 Pulmonary Arterial Hypertension (PAH) Medicine Segment by Application

2.4.1 Secondary Pulmonary Hypertension (SPH)

2.4.2 Primary Pulmonary Hypertension (PPH)

2.5 Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application

2.5.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sale Market Share by Application (2017-2022)

2.5.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue and Market Share by Application (2017-2022)

2.5.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Sale Price by Application (2017-2022)

3 Global Pulmonary Arterial Hypertension (PAH) Medicine by Company

3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Breakdown Data by Company

3.1.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Annual Sales by Company (2020-2022)

3.1.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Company (2020-2022)

3.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Annual Revenue by Company (2020-2022)

3.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Company (2020-2022)

3.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Company (2020-2022)

3.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Sale Price by Company

3.4 Key Manufacturers Pulmonary Arterial Hypertension (PAH) Medicine Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Pulmonary Arterial Hypertension (PAH) Medicine Product Location Distribution

3.4.2 Players Pulmonary Arterial Hypertension (PAH) Medicine Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Pulmonary Arterial Hypertension (PAH) Medicine by Geographic Region

4.1 World Historic Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Geographic Region (2017-2022)

4.1.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Annual Revenue by Geographic Region

4.2 World Historic Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country/Region (2017-2022)

4.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Annual Sales by Country/Region (2017-2022)

4.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Annual Revenue by Country/Region

4.3 Americas Pulmonary Arterial Hypertension (PAH) Medicine Sales Growth

4.4 APAC Pulmonary Arterial Hypertension (PAH) Medicine Sales Growth

4.5 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Growth

4.6 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Growth

5 Americas

5.1 Americas Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country

5.1.1 Americas Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2017-2022)

5.1.2 Americas Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2017-2022)

5.2 Americas Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type

5.3 Americas Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region

6.1.1 APAC Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2017-2022)

6.1.2 APAC Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region (2017-2022)

6.2 APAC Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type

6.3 APAC Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 Europe

7.1 Europe Pulmonary Arterial Hypertension (PAH) Medicine by Country

7.1.1 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2017-2022)

7.1.2 Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2017-2022)

7.2 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type

7.3 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine by Country

8.1.1 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2017-2022)

8.1.2 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2017-2022)

8.2 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type

8.3 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Pulmonary Arterial Hypertension (PAH) Medicine

10.3 Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH) Medicine

10.4 Industry Chain Structure of Pulmonary Arterial Hypertension (PAH) Medicine

11 Marketing, Distributors and Customer

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Pulmonary Arterial Hypertension (PAH) Medicine Distributors

11.3 Pulmonary Arterial Hypertension (PAH) Medicine Customer

12 World Forecast Review for Pulmonary Arterial Hypertension (PAH) Medicine by Geographic Region

12.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size Forecast by Region

12.1.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Forecast by Region (2023-2028)

12.1.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Annual Revenue Forecast by Region (2023-2028)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Pulmonary Arterial Hypertension (PAH) Medicine Forecast by Type

12.7 Global Pulmonary Arterial Hypertension (PAH) Medicine Forecast by Application

13 Key Players Analysis

13.1 Pfizer

13.1.1 Pfizer Company Information

13.1.2 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Product Offered

13.1.3 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue, Price and Gross Margin (2020-2022)

13.1.4 Pfizer Main Business Overview

13.1.5 Pfizer Latest Developments

13.2 Gilead Sciences

13.2.1 Gilead Sciences Company Information

13.2.2 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Product Offered

13.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue, Price and Gross Margin (2020-2022)

13.2.4 Gilead Sciences Main Business Overview

13.2.5 Gilead Sciences Latest Developments

13.3 Eli Lilly

13.3.1 Eli Lilly Company Information

13.3.2 Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Product Offered

13.3.3 Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue, Price and Gross Margin (2020-2022)

13.3.4 Eli Lilly Main Business Overview

13.3.5 Eli Lilly Latest Developments

13.4 Actelion Pharmaceuticals

13.4.1 Actelion Pharmaceuticals Company Information

13.4.2 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product Offered

13.4.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue, Price and Gross Margin (2020-2022)

13.4.4 Actelion Pharmaceuticals Main Business Overview

13.4.5 Actelion Pharmaceuticals Latest Developments

13.5 United Therapeutics Corporation

13.5.1 United Therapeutics Corporation Company Information

13.5.2 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Product Offered

13.5.3 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue, Price and Gross Margin (2020-2022)

13.5.4 United Therapeutics Corporation Main Business Overview

13.5.5 United Therapeutics Corporation Latest Developments

14 Research Findings and Conclusion

Table 1. Pulmonary Arterial Hypertension (PAH) Medicine Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)

Table 2. Pulmonary Arterial Hypertension (PAH) Medicine Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)

Table 3. Major Players of Calcium Channel Blockers

Table 4. Major Players of Novel Targeted Drugs

Table 5. Major Players of Other

Table 6. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2017-2022) & (K Units)

Table 7. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2017-2022)

Table 8. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Type (2017-2022) & ($ million)

Table 9. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Type (2017-2022)

Table 10. Global Pulmonary Arterial Hypertension (PAH) Medicine Sale Price by Type (2017-2022) & (USD/Units)

Table 11. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2017-2022) & (K Units)

Table 12. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2017-2022)

Table 13. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Application (2017-2022)

Table 14. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Application (2017-2022)

Table 15. Global Pulmonary Arterial Hypertension (PAH) Medicine Sale Price by Application (2017-2022) & (USD/Units)

Table 16. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Company (2020-2022) & (K Units)

Table 17. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Company (2020-2022)

Table 18. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Company (2020-2022) ($ Millions)

Table 19. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Company (2020-2022)

Table 20. Global Pulmonary Arterial Hypertension (PAH) Medicine Sale Price by Company (2020-2022) & (USD/Units)

Table 21. Key Manufacturers Pulmonary Arterial Hypertension (PAH) Medicine Producing Area Distribution and Sales Area

Table 22. Players Pulmonary Arterial Hypertension (PAH) Medicine Products Offered

Table 23. Pulmonary Arterial Hypertension (PAH) Medicine Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 24. New Products and Potential Entrants

Table 25. Mergers & Acquisitions, Expansion

Table 26. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Geographic Region (2017-2022) & (K Units)

Table 27. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share Geographic Region (2017-2022)

Table 28. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Geographic Region (2017-2022) & ($ millions)

Table 29. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Geographic Region (2017-2022)

Table 30. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country/Region (2017-2022) & (K Units)

Table 31. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country/Region (2017-2022)

Table 32. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country/Region (2017-2022) & ($ millions)

Table 33. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Country/Region (2017-2022)

Table 34. Americas Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2017-2022) & (K Units)

Table 35. Americas Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2017-2022)

Table 36. Americas Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2017-2022) & ($ Millions)

Table 37. Americas Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Country (2017-2022)

Table 38. Americas Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2017-2022) & (K Units)

Table 39. Americas Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2017-2022)

Table 40. Americas Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2017-2022) & (K Units)

Table 41. Americas Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2017-2022)

Table 42. APAC Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2017-2022) & (K Units)

Table 43. APAC Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Region (2017-2022)

Table 44. APAC Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region (2017-2022) & ($ Millions)

Table 45. APAC Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Region (2017-2022)

Table 46. APAC Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2017-2022) & (K Units)

Table 47. APAC Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2017-2022)

Table 48. APAC Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2017-2022) & (K Units)

Table 49. APAC Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2017-2022)

Table 50. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2017-2022) & (K Units)

Table 51. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2017-2022)

Table 52. Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2017-2022) & ($ Millions)

Table 53. Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Country (2017-2022)

Table 54. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2017-2022) & (K Units)

Table 55. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2017-2022)

Table 56. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2017-2022) & (K Units)

Table 57. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2017-2022)

Table 58. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2017-2022) & (K Units)

Table 59. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2017-2022)

Table 60. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2017-2022) & ($ Millions)

Table 61. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Country (2017-2022)

Table 62. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2017-2022) & (K Units)

Table 63. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2017-2022)

Table 64. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2017-2022) & (K Units)

Table 65. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2017-2022)

Table 66. Key Market Drivers & Growth Opportunities of Pulmonary Arterial Hypertension (PAH) Medicine

Table 67. Key Market Challenges & Risks of Pulmonary Arterial Hypertension (PAH) Medicine

Table 68. Key Industry Trends of Pulmonary Arterial Hypertension (PAH) Medicine

Table 69. Pulmonary Arterial Hypertension (PAH) Medicine Raw Material

Table 70. Key Suppliers of Raw Materials

Table 71. Pulmonary Arterial Hypertension (PAH) Medicine Distributors List

Table 72. Pulmonary Arterial Hypertension (PAH) Medicine Customer List

Table 73. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecast by Region (2023-2028) & (K Units)

Table 74. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Forecast by Region

Table 75. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Forecast by Region (2023-2028) & ($ millions)

Table 76. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share Forecast by Region (2023-2028)

Table 77. Americas Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecast by Country (2023-2028) & (K Units)

Table 78. Americas Pulmonary Arterial Hypertension (PAH) Medicine Revenue Forecast by Country (2023-2028) & ($ millions)

Table 79. APAC Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecast by Region (2023-2028) & (K Units)

Table 80. APAC Pulmonary Arterial Hypertension (PAH) Medicine Revenue Forecast by Region (2023-2028) & ($ millions)

Table 81. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecast by Country (2023-2028) & (K Units)

Table 82. Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue Forecast by Country (2023-2028) & ($ millions)

Table 83. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecast by Country (2023-2028) & (K Units)

Table 84. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue Forecast by Country (2023-2028) & ($ millions)

Table 85. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecast by Type (2023-2028) & (K Units)

Table 86. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share Forecast by Type (2023-2028)

Table 87. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Forecast by Type (2023-2028) & ($ Millions)

Table 88. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share Forecast by Type (2023-2028)

Table 89. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecast by Application (2023-2028) & (K Units)

Table 90. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share Forecast by Application (2023-2028)

Table 91. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Forecast by Application (2023-2028) & ($ Millions)

Table 92. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share Forecast by Application (2023-2028)

Table 93. Pfizer Basic Information, Pulmonary Arterial Hypertension (PAH) Medicine Manufacturing Base, Sales Area and Its Competitors

Table 94. Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Product Offered

Table 95. Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Revenue ($ Million), Price (USD/Units) and Gross Margin (2020-2022)

Table 96. Pfizer Main Business

Table 97. Pfizer Latest Developments

Table 98. Gilead Sciences Basic Information, Pulmonary Arterial Hypertension (PAH) Medicine Manufacturing Base, Sales Area and Its Competitors

Table 99. Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Product Offered

Table 100. Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Revenue ($ Million), Price (USD/Units) and Gross Margin (2020-2022)

Table 101. Gilead Sciences Main Business

Table 102. Gilead Sciences Latest Developments

Table 103. Eli Lilly Basic Information, Pulmonary Arterial Hypertension (PAH) Medicine Manufacturing Base, Sales Area and Its Competitors

Table 104. Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Product Offered

Table 105. Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Revenue ($ Million), Price (USD/Units) and Gross Margin (2020-2022)

Table 106. Eli Lilly Main Business

Table 107. Eli Lilly Latest Developments

Table 108. Actelion Pharmaceuticals Basic Information, Pulmonary Arterial Hypertension (PAH) Medicine Manufacturing Base, Sales Area and Its Competitors

Table 109. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product Offered

Table 110. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Revenue ($ Million), Price (USD/Units) and Gross Margin (2020-2022)

Table 111. Actelion Pharmaceuticals Main Business

Table 112. Actelion Pharmaceuticals Latest Developments

Table 113. United Therapeutics Corporation Basic Information, Pulmonary Arterial Hypertension (PAH) Medicine Manufacturing Base, Sales Area and Its Competitors

Table 114. United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Product Offered

Table 115. United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Revenue ($ Million), Price (USD/Units) and Gross Margin (2020-2022)

Table 116. United Therapeutics Corporation Main Business

Table 117. United Therapeutics Corporation Latest Developments

List of Figures

Figure 1. Picture of Pulmonary Arterial Hypertension (PAH) Medicine

Figure 2. Pulmonary Arterial Hypertension (PAH) Medicine Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Growth Rate 2017-2028 (K Units)

Figure 7. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate 2017-2028 ($ Millions)

Figure 8. Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2021 & 2028) & ($ millions)

Figure 9. Product Picture of Calcium Channel Blockers

Figure 10. Product Picture of Novel Targeted Drugs

Figure 11. Product Picture of Other

Figure 12. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type in 2021

Figure 13. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Type (2017-2022)

Figure 14. Pulmonary Arterial Hypertension (PAH) Medicine Consumed in Secondary Pulmonary Hypertension (SPH)

Figure 15. Global Pulmonary Arterial Hypertension (PAH) Medicine Market: Secondary Pulmonary Hypertension (SPH) (2017-2022) & (K Units)

Figure 16. Pulmonary Arterial Hypertension (PAH) Medicine Consumed in Primary Pulmonary Hypertension (PPH)

Figure 17. Global Pulmonary Arterial Hypertension (PAH) Medicine Market: Primary Pulmonary Hypertension (PPH) (2017-2022) & (K Units)

Figure 18. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2017-2022)

Figure 19. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Application in 2021

Figure 20. Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market by Company in 2021 ($ Million)

Figure 21. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Company in 2021

Figure 22. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Geographic Region (2017-2022)

Figure 23. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Geographic Region in 2021

Figure 24. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Region (2017-2022)

Figure 25. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Country/Region in 2021

Figure 26. Americas Pulmonary Arterial Hypertension (PAH) Medicine Sales 2017-2022 (K Units)

Figure 27. Americas Pulmonary Arterial Hypertension (PAH) Medicine Revenue 2017-2022 ($ Millions)

Figure 28. APAC Pulmonary Arterial Hypertension (PAH) Medicine Sales 2017-2022 (K Units)

Figure 29. APAC Pulmonary Arterial Hypertension (PAH) Medicine Revenue 2017-2022 ($ Millions)

Figure 30. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales 2017-2022 (K Units)

Figure 31. Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue 2017-2022 ($ Millions)

Figure 32. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales 2017-2022 (K Units)

Figure 33. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue 2017-2022 ($ Millions)

Figure 34. Americas Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country in 2021

Figure 35. Americas Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Country in 2021

Figure 36. United States Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth 2017-2022 ($ Millions)

Figure 37. Canada Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth 2017-2022 ($ Millions)

Figure 38. Mexico Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth 2017-2022 ($ Millions)

Figure 39. Brazil Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth 2017-2022 ($ Millions)

Figure 40. APAC Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Region in 2021

Figure 41. APAC Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Regions in 2021

Figure 42. China Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth 2017-2022 ($ Millions)

Figure 43. Japan Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth 2017-2022 ($ Millions)

Figure 44. South Korea Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth 2017-2022 ($ Millions)

Figure 45. Southeast Asia Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth 2017-2022 ($ Millions)

Figure 46. India Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth 2017-2022 ($ Millions)

Figure 47. Australia Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth 2017-2022 ($ Millions)

Figure 48. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country in 2021

Figure 49. Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Country in 2021

Figure 50. Germany Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth 2017-2022 ($ Millions)

Figure 51. France Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth 2017-2022 ($ Millions)

Figure 52. UK Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth 2017-2022 ($ Millions)

Figure 53. Italy Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth 2017-2022 ($ Millions)

Figure 54. Russia Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth 2017-2022 ($ Millions)

Figure 55. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country in 2021

Figure 56. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Country in 2021

Figure 57. Egypt Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth 2017-2022 ($ Millions)

Figure 58. South Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth 2017-2022 ($ Millions)

Figure 59. Israel Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth 2017-2022 ($ Millions)

Figure 60. Turkey Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth 2017-2022 ($ Millions)

Figure 61. GCC Country Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth 2017-2022 ($ Millions)

Figure 62. Manufacturing Cost Structure Analysis of Pulmonary Arterial Hypertension (PAH) Medicine in 2021

Figure 63. Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH) Medicine

Figure 64. Industry Chain Structure of Pulmonary Arterial Hypertension (PAH) Medicine

Figure 65. Channels of Distribution

Figure 66. Distributors Profiles